Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBIT: 2019-2024

Historic EBIT for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to -$372.5 million.

  • Relay Therapeutics' EBIT rose 16.58% to -$80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.1 million, marking a year-over-year increase of 13.85%. This contributed to the annual value of -$372.5 million for FY2024, which is 0.14% up from last year.
  • Per Relay Therapeutics' latest filing, its EBIT stood at -$372.5 million for FY2024, which was up 0.14% from -$373.0 million recorded in FY2023.
  • Relay Therapeutics' EBIT's 5-year high stood at -$55.8 million during FY2020, with a 5-year trough of -$373.0 million in FY2023.
  • In the last 3 years, Relay Therapeutics' EBIT had a median value of -$372.5 million in 2024 and averaged -$348.2 million.
  • In the last 5 years, Relay Therapeutics' EBIT skyrocketed by 33.61% in 2020 and then plummeted by 553.63% in 2021.
  • Over the past 5 years, Relay Therapeutics' EBIT (Yearly) stood at -$55.8 million in 2020, then slumped by 553.63% to -$364.7 million in 2021, then climbed by 17.94% to -$299.3 million in 2022, then dropped by 24.63% to -$373.0 million in 2023, then climbed by 0.14% to -$372.5 million in 2024.